Generic Drug Market Has Grown At a CAGR of Around 10% During Last Few Years

Imarc

Consulting Services

www.imarcgroup.com

Growth in the Generic Drug Market Will be Critical in Cutting down Rising Healthcare Costs

Copyright Š 2016 International Market Analysis Research & Consulting (IMARC). All Rights Reserved

Imarc

About IMARC Group

Report Description

www.imarcgroup.com

The International Market Analysis Research and Consulting Group is a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Growth in the Generic Drug Market Will be Critical in Cutting down Rising Healthcare Costs

Generic drugs are expected to witness strong growth in both developed and emerging markets. Patent expiries of a number of blockbuster branded drugs and the huge cost savings that can be potentially achieved from the utilisation of generic drugs are expected to represent the key factors catalysing this growth.

A generic drug is a pharmaceutical product which is a bio-equivalent of the branded drug and is normally manufactured after the expiration of the patent rights of the branded one. Over the past few decades, the global market for generic drugs has evolved considerably and currently represents a global multibillion dollar market.

The growth of the generic drug market has expanded primarily due to several factors. Owing to the low research and development requirements, the costs involved in developing and manufacturing a generic drug is significantly lower as compared to a branded drug. This allows generic drug manufacturers to price their products significantly lower compared to branded drugs.

IMARC Group, a leading market research company based in India, finds that the market has grown at a CAGR of around 10% during 2010-2015. According to its latest report entitled “Generic Drug Market: Industry Trends, Manufacturing Process, Plant Setup, Machinery, Raw Materials, Cost and Revenue�, healthcare costs on account of rising aging population and an increasing prevalence of chronic diseases have been rising robustly across the globe. Substitution of low-cost generic drugs for innovator products has proved to be a successful strategy in reducing healthcare costs . As a result, Governments and healthcare providers in both developed and emerging markets have identified the growth of the generic market as imperative to their country’s long term economic health.

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Browse press release: http://www.imarcgroup.com/growth-in-the-generic-drug-market

The report provides a comprehensive analysis on the global generic market and has segmented this market on the basis of key regions. The report finds that the US currently represents the world’s biggest market for generic drugs, followed by China, Europe, India, Brazil, and South Korea. The report also expects that driven by patent expiries of a number of blockbuster branded drugs and the huge cost savings that can be potentially achieved from the utilisation of generics, the market for generic drugs will witness strong growth in both developed and emerging markets.

Findings from the report also suggest that the market for generic drugs has low concentration with low entry barriers encouraging a number of new players to enter this market. As a result, the market is highly competitive with a significant price erosion. Some of the larger players in this market such as Teva Pharmaceuticals, Novartis, Actavis, Mylan, Sun Pharmaceuticals, etc. are, however, still able to maintain a high profitability as a result of global diversification and launching speciality products.

This new report provides a comprehensive understanding on the dynamics of the global generic drug market. The study effectively provides both macro and micro elements of the industry like market drivers, challenges, competitive landscape, pricing, key regions, manufacturing process, raw material requirements, project cost, project economics, machinery details, value chain, expected returns on investment, profit margins, etc. This report can act as an excellent tool for anyone who plans to enter the generic drug market.

Enquiry for sample report or more details, click here: http://www.imarcgroup.com/enquiry-form

Imarc

Generic Drug Market

Report Description

www.imarcgroup.com

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Table of Contents 1 Research Methodology 2 Executive Summary 3 Introduction 4 Global Generic Drug Industry Analysis 4.1 Classification of Generic Drugs 4.2 Market Trends 4.2.1 Current and Historical Market Trends 4.2.2 Market Breakup by Region 4.2.3 Competitive Structure and Major Players in the Generic Drug Industry 4.2.4 Market Forecast 4.3 Value Chain Analysis of Generic Drugs 4.4 Key Success Factors for Generic Manufacturers 4.6 Regulations in the Generic Industry 5 Manufacturing Process of Generic Drugs 5.1 Detailed Process Flow 5.2 Generic Drugs Manufacturing Plant: Raw Material Requirements 6 Project Details, Requirements and Costs Involved 6.1 Land, Location and Site Development 6.2 Plant Layout 6.3 Plant Machinery 6.4 Machinery Pictures 6.5 Raw Materials

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

6.6 Packaging 6.7 Utilities 6.8 Manpower 6.9 Other Capital Investments 7 Generic Drug Manufacturing Plant: Project Economics 7.1 Capital Cost of the Project 7.2 Loans and Financial Assistance 7.3 Techno-Economic Parameters 7.4 Product Pricing 7.5 Income Projections 7.6 Expenditure Projections 7.7 Financial Analysis List of Figures Figure 4 1: Global: Generic Drug Market: Sales Value (in US$ Billion), 2011-2015 Figure 4 2: Global: Generic Drug Market: Breakup by Country (in %), 2015 Figure 4 3: Global: Generic Drug Market Forecast: Sales Value (in US$ Billion), 2015-2020 Figure 4 4: Global: Generic Drug Market: Value Chain Figure 6 1: Generic Drug Manufacturing: Detailed Process Flow and Various Types of Unit Operations Involved Figure 6 2: Generic Drug Manufacturing Process: Conversion Rate of Feedstocks Figure 7 1: Generic Drug Manufacturing Plant: Proposed Plant Layout Figure 7 2: Generic Drug Manufacturing Plant: Primary Packaging Figure 7 3: Generic Drug Manufacturing Plant: Secondary Packaging

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Figure 7 4: Generic Drug Manufacturing Plant: Tertiary Packaging Figure 8 1: Generic Drug Manufacturing Plant: Breakup of Capital Costs (in %) Figure 8 2: Generic Drug Manufacturing Plant: Breakup of Production Costs (in %) List of Tables Table 4 1: Global: Generic Drug Market: Revenues of Key Players (in US$ Billion), 2015 Table 7 1: Generic Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$) Table 7 2: Generic Drug Manufacturing Plant: Costs Related to Civil Works (in US$) Table 7 3: Generic Drug Manufacturing Plant: Machinery Costs (in US$) Table 7 4: Generic Drug Manufacturing Plant: Raw Material Requirements (in Kg/Day) Table 7 5: Generic Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$) Table 7 6: Generic Drug Manufacturing Plant: Costs Related to Other Capital Investments Table 8 1: Generic Drug Manufacturing Plant: Capital Costs (in US$) Table 8 2: Details of Financial Assistance Offered by Financial Institutions Table 8 3: Generic Drug Manufacturing Plant: Loan Instalments Table 8 4: Generic Drug Manufacturing Plant: Techno- Economic Parameters Table 8 5: Generic Drug Manufacturing Plant: Income Projections (in US$) Table 8 6: Generic Drug Manufacturing Plant: Expenditure Projections (in US$) Table 8 7: Generic Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability Table 8 8: Generic Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

To buy the complete report or to get a free sample, please contact:

IMARC Group Asia: Email: apac@imarcgroup.com Phone: +91-120-415-5099

IMARC Group North America: Email: america@imarcgroup.com Phone: +1-631-791-1145

IMARC Group Europe, Middle East & Africa: Email: ema@imarcgroup.com Phone: +44-702-409-7331

To know more please visit: http://www.imarcgroup.com/generic-drug-manufacturing-plant

Imarc

Report Description and Highlights

Report Description

www.imarcgroup.com

Š 2016 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing.

International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

http://www.imarcgroup.com Stay With Us:

TELEPHONE: +91-120-4155099 E-MAIL: sales@imarcgroup.com